Dose escalation of carboplatin and cyclophosphamide supported by GM-CSF in the treatment of patients with advanced ovarian cancer (FIGO III and IV) - A phase I study

Onkologie

Volumn 22, Issue 6, 1999, Pages 502-506

  Sieger, D ^b   D'Addario, G ^c   Lorenz, U ^c   Bacchi, M ^a   Thurlimann B ^c  

^a Schweizerisches Inst Angew K   (Switzerland)

^b Kantonsspital Muensterlingen   (Switzerland)

^c NONE

Author keywords

Carboplatin; Cyclophosphamide; Dose escalation; Dose intensity; GM CSF; Ovarian cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; LEUKOPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 0033393597     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000027037     Document Type: Article

References (24)

1. NIH, CDCS: Ovarian cancer: Screening, treatment, and follow up. Gynecol Oncol 1994;55:4-14.
2. Hochuli E: Ovarialkarzinom; in Hochuli E (Hrsg): Geburtshilfe, Gynäkologie und Grenzgebiete. Bern, Huber, 1996, pp 248-259.
3. Westhoff C: Ovarian cancer. Annu Rev Publ Health 1996;17:85-96.
4. Thigpen JT, Vance RB, Lambuth BW: Ovarian carcinoma: The role of chemotherapy. Semin Oncol 1988;15:16-23.
5. Martoni A, Panetta A, Angelelli B, Melotti B, Pannuti F: A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma. J Chemother 1993;5:47-51.
6. Rusthoven J: Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 1991; 83:1748-1753.
7. Rusthoven J, Eisenhauer E, Mazurka CJ: A phase-I study of GM-CSF, cyclophosphamide (CP) and escalating dose of carboplatin (CBDCA) in chemotherapy-naive patients with ovarian cancer. Gynecol Oncol 1991;40:169-170.
8. Nitz U, Jackisch C, Weise W, Schiller E, Illiger HJ: Dose intensified carboplatin monotherapy in advanced ovarian cancer. Zentralbl Gynäkol 1994;116: 549-554.
9. Reed E: High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. J Clin Oncol 1993;11:2118-2126.
10. Kehoe S, Poole CJ, Stanley A, Earl HM, Blackledge GR: A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. Br J Cancer 1994;69:537-540.
11. Edmonson JH, Colon-Otero G, Long HJ: Granulocyte-macrophage colony-stimulating factor permits escalation of carboplatin doses. Proc Am Soc Clin Oncol 1990;9:330.
12. Fanning J, Hilgers RD: Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer. Gynecol Oncol 1996;63:323-327.
13. Calvert AH: Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: A phase I dose-intensity escalation study. Semin Oncol 1994;21(suppl 12):1-6.
14. Wandl UB, Niederle N: The concept of dose intensification in the treatment of neoplastic disease. Infection 1992;20:suppl 2:S107-110.
15. Levin L, Hryniuk WM: Dose intensity analysis of advanced ovarian carcinoma. J Clin Oncol 1987;5: 576-581.
16. Ozols RF, Young RC: High-dose cisplatin chemotherapy in ovarian cancer. Semin Oncol 1985;12: 21-30.
17. Ozols RF, Ostchega Y, Curt G: High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 1987;5:197-201.
18. McGuire WP: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 1995; 13:1589-1599.
19. Repetto L: The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 1993;29a:181-184.
20. Fennelly D, Schneider J: Role of chemotherapy dose intensification in the treatment of advanced ovarian cancer. Oncology 1995;9:911-921.
21. Fennelly D: Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: A phase I trial. Cancer Res 1994;54:6137-6142.
22. Shea TC: Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992;10:464-473.
23. McGuire WP: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
24. Piccart MJ, Bertelsen K, Stuart G, James K, Cassidy J, Pecorelli S: Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc Am Soc Clin Oncol 1997;16:1258.